Bleomycin, vinblastine and dacarbazine combined with nonpegylated liposomal doxorubicin (MBVD) in elderly (≥70 years) or cardiopathic patients with Hodgkin lymphoma: a phase-II study from Fondazione Italiana Linfomi (FIL)

Clicks: 283
ID: 120956
2019
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #6 of 8 articles by views in Leukemia & lymphoma

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
This phase-II study assessed activity and toxicity of substituting conventional doxorubicin with nonpegylated liposomal doxorubicin in the conventional ABVD regimen for the treatment of elderly or cardiopathic patients with HL. Stage I-IIA and IIB-IV patients were treated with three courses of MBVD …
Reference Key
f2019leukemiableomycin, Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Salvi F;Luminari S;Tucci A;Massidda S;Liberati AM;Stelitano C;Zanni M;Re A;Centurioni R;Freilone R;Musuraca G;Nassi L;Patti C;Arcari A;Tani M;Pulsoni A;Pavone V;Volpetti S;Peli A;Evangelista A;Spina M;Ladetto M;Merli F;;
Journal Leukemia & lymphoma
Year 2019
DOI
DOI not found
URL
https://www.pubmed.gov/31282794/
Keywords
National Center for Biotechnology Information NCBI NLM MEDLINE pubmed abstract nih national institutes of health national library of medicine pmid:31282794 doi:10.1080/10428194.2019.1608529 flavia salvi stefano luminari francesco merli

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.